Oruka Therapeutics (NASDAQ:ORKA) Upgraded by Wall Street Zen to Hold Rating

Key Points

• Wall Street Zen upgraded Oruka Therapeutics from “sell” to “hold,” while broader analyst sentiment remains positive: 10 analysts rate the stock a Buy and one rates it a Sell, producing a “Moderate Buy” consensus and a $134.30 average price target.
• ORKA opened at $98.82, near its 52-week high of $100.34, with a $5.96 billion market capitalization. The company reported a quarterly loss of $0.48 per share, beating estimates of a $0.52 loss.
• Insiders have sold 188,406 shares worth about $12.0 million over the past 90 days, while institutional investors and hedge funds own 56.44% of the stock.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a report issued on Saturday.

ORKA has been the topic of several other research reports. Leerink Partners set a $120.00 price target on Oruka Therapeutics in a research report on Thursday, April 30th. UBS Group increased their price objective on Oruka Therapeutics from $100.00 to $130.00 and gave the stock a "buy" rating in a research report on Wednesday, July 1st. BTIG Research reiterated a "buy" rating and issued a $151.00 target price on shares of Oruka Therapeutics in a research note on Monday, July 13th. Barclays boosted their target price on Oruka Therapeutics from $78.00 to $160.00 and gave the company an "overweight" rating in a report on Monday, April 27th. Finally, Guggenheim set a $200.00 price target on Oruka Therapeutics and gave the stock a "buy" rating in a research note on Monday, April 27th. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $134.30.

Oruka Therapeutics Stock Performance

Shares of Oruka Therapeutics stock opened at $98.82 on Friday. The company has a market capitalization of $5.96 billion, a P/E ratio of -50.94 and a beta of -0.34. Oruka Therapeutics has a 1 year low of $12.84 and a 1 year high of $100.34. The company's fifty day moving average is $82.59 and its two-hundred day moving average is $60.06.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last announced its earnings results on Wednesday, May 13th. The company reported ($0.48) EPS for the quarter, beating analysts' consensus estimates of ($0.52) by $0.04. As a group, equities analysts expect that Oruka Therapeutics will post -2.06 earnings per share for the current year.

Insider Activity at Oruka Therapeutics

In other Oruka Therapeutics news, SVP Arjun Agarwal sold 9,999 shares of the business's stock in a transaction on Monday, July 13th. The shares were sold at an average price of $84.63, for a total transaction of $846,215.37. Following the sale, the senior vice president directly owned 15,312 shares in the company, valued at approximately $1,295,854.56. The trade was a 39.50% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Joana Goncalves sold 7,947 shares of the company's stock in a transaction on Monday, June 15th. The stock was sold at an average price of $69.28, for a total transaction of $550,568.16. Following the transaction, the insider directly owned 32,718 shares in the company, valued at approximately $2,266,703.04. This trade represents a 19.54% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 188,406 shares of company stock valued at $12,019,683 over the last 90 days. Company insiders own 23.49% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Legal & General Group Plc acquired a new stake in shares of Oruka Therapeutics during the 2nd quarter valued at approximately $28,000. BNP Paribas Financial Markets grew its holdings in shares of Oruka Therapeutics by 464.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company's stock worth $31,000 after acquiring an additional 2,306 shares during the period. Royal Bank of Canada grew its holdings in shares of Oruka Therapeutics by 47.2% in the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company's stock worth $34,000 after acquiring an additional 365 shares during the period. Los Angeles Capital Management LLC purchased a new position in Oruka Therapeutics in the 4th quarter valued at approximately $37,000. Finally, PNC Financial Services Group Inc. purchased a new position in Oruka Therapeutics in the 3rd quarter valued at approximately $39,000. 56.44% of the stock is currently owned by institutional investors and hedge funds.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company's proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company's lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source